Mesothelioma Cancer Resources Blog

Targeting biomarkers, or the unique identifying genetic traits of tumors, in the treatment of lung cancer is touted as the best way to attack the aggressive cancer. However, researchers are now reporting that unless the cancer is identified and treated early, multiple biomarkers take over the tumors leaving many of the cancer cells unaffected by …

Mesothelioma is one of the most aggressive and challenging cancers to treat. The infected cells fight off standard cancer treatments and continue to grow and divide leaving doctors and patients frustrated at the inability to stop the rogue cells. Now, researchers say that they are working on building a Pac-Man-like artificial cell that can gobble …

This article is a correction from the original that inadvertently stated that defactinib was approved by the U.S. FDA. It should have said paclitaxel was approved by the FDA. In November, MesotheliomaHelp announced the start of the global clinical trial named COMMAND (Control Of Mesothelioma with MAiNtenance Defactinib), to assess the overall survival and progression …